Literature DB >> 12671457

Respiratory syncytial virus bronchiolitis: supportive care and therapies designed to overcome airway obstruction.

Howard B Panitch1.   

Abstract

Treatment of respiratory syncytial virus bronchiolitis rests primarily on supportive care with oxygen and fluid management. Other therapies commonly used include bronchodilators, corticosteroids and ribavirin, when considered appropriate. Small studies have also suggested that exogenous surfactant, helium/oxygen mixtures (heliox) and combination therapies may offer clinical benefit as well. Management of bronchiolitis can be facilitated by (1) recognizing the risks and benefits of various therapies, (2) understanding the markers of disease severity and (3) gaining familiarity with the time course of viral replication compared with presentation of symptoms. Although oxygen administration and judicious fluid replacement are the only interventions proved to be of reliable benefit to infants with bronchiolitis, newer studies support a role for adjunctive therapies aimed at relieving airway obstruction, especially when administered very early in the course of the illness or given to infants with more severe disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12671457     DOI: 10.1097/01.inf.0000053890.66801.97

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  11 in total

Review 1.  Respiratory syncytial virus bronchiolitis.

Authors:  Alexander K C Leung; James D Kellner; H Dele Davies
Journal:  J Natl Med Assoc       Date:  2005-12       Impact factor: 1.798

Review 2.  Nebulised hypertonic saline solution for acute bronchiolitis in infants.

Authors:  Linjie Zhang; Raúl A Mendoza-Sassi; Claire Wainwright; Terry P Klassen
Journal:  Cochrane Database Syst Rev       Date:  2017-12-21

3.  Reduced clearance of respiratory syncytial virus infection in a preterm lamb model.

Authors:  David K Meyerholz; Branka Grubor; Sasha J Fach; Randy E Sacco; Howard D Lehmkuhl; Jack M Gallup; Mark R Ackermann
Journal:  Microbes Infect       Date:  2004-11       Impact factor: 2.700

4.  Suctioning and length of stay in infants hospitalized with bronchiolitis.

Authors:  Grant M Mussman; Michelle W Parker; Angela Statile; Heidi Sucharew; Patrick W Brady
Journal:  JAMA Pediatr       Date:  2013-05       Impact factor: 16.193

5.  Multicenter Observational Study of the Use of Nebulized Hypertonic Saline to Treat Children Hospitalized for Bronchiolitis From 2008 to 2014.

Authors:  Joshua Davis; Amy D Thompson; Jonathan M Mansbach; Pedro A Piedra; Kohei Kasagawa; Ashley F Sullivan; Janice A Espinola; Carlos A Camargo
Journal:  Hosp Pediatr       Date:  2017-07-31

6.  Respiratory syncytial virus infection in children with neuromuscular impairment.

Authors:  Arne Simon; Julia Prusseit; Andreas Müller
Journal:  Open Microbiol J       Date:  2011-12-30

7.  Combined fluticasone propionate and salmeterol reduces RSV infection more effectively than either of them alone in allergen-sensitized mice.

Authors:  Rajeswari Singam; Prasanna K Jena; Sumita Behera; Gary R Hellermann; Richard F Lockey; Dennis Ledford; Shyam S Mohapatra
Journal:  Virol J       Date:  2006-05-23       Impact factor: 4.099

8.  The impact of viral dynamics on the clinical severity of infants with respiratory syncytial virus bronchiolitis.

Authors:  Lili Zhou; Qiuyan Xiao; Yao Zhao; Ailong Huang; Luo Ren; Enmei Liu
Journal:  J Med Virol       Date:  2015-04-23       Impact factor: 2.327

9.  Nutritional status, breastfeeding, and evolution of Infants with acute viral bronchiolitis.

Authors:  Cristina T L Dornelles; Jefferson P Piva; Paulo J C Marostica
Journal:  J Health Popul Nutr       Date:  2007-09       Impact factor: 2.000

10.  Epidemiology of respiratory syncytial virus in children in Cyprus during three consecutive winter seasons (2010-2013): age distribution, seasonality and association between prevalent genotypes and disease severity.

Authors:  C Panayiotou; J Richter; M Koliou; N Kalogirou; E Georgiou; C Christodoulou
Journal:  Epidemiol Infect       Date:  2014-01-24       Impact factor: 4.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.